Transjugular intrahepatic portosystemic shunts vs Conventional treatment: All‐cause mortality
It is very uncertain whether transjugular intrahepatic portosystemic shunts changes all‐cause mortality compared with conventional treatment (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Transjugular intrahepatic portosystemic shunts vs conventional treatment All‐cause mortality · adults with hepatorenal syndrome It is very uncertain whether transjugular intrahepatic portosystemic shunts changes all‐cause mortality compared with conventional treatment (very low certainty). Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome (2024) · Cochrane Headline outcomes only | RR 0.88 [0.55, 1.38] | 2 studies · 130 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome 2024 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.